Genmab — Marts 2025

[lahn1]

Jeg ville som ledelse også sagsøge Gmab for at dække over mit $10Bn køb som nu ser mindre godt ud. Rart at kunne skyde skylden på tyveri

[Solsen]

Abbvie køber Immunogen 30. november 2023 https://www.fiercepharma.com/pharma/abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field på SITC 3. november offentliggør Profound data fra Rina-S som de nok burde have været opmærksom på https://www.biospace.com/profoundbio-presents-promising-data-on-adc-programs-including-early-clinical-results-of-rinatabart-sesutecan-in-ovarian-and-endometrial-cancers-at-sitc-2023

[Solsen]

Mon det ikke er tidligere medarbejdere i immunogen vi skal søge eller ?

[Raun]

Vi kan også sætte det hele på hovedet..... Det kostede 4% i reklamepenge.... Det har afstedkommet at markedet nu for alvor har fået øje på RinaS.... Så skal vi egentlig ikke bare takke Abbvie

[Solsen]

Abbvies opfølger IMGN151 er i fase 1 siden december 2022 og har en DAR på 3,5 med deres payload DM21 https://aacrjournals.org/cancerres/article/80/16_Supplement/2890/642251/Abstract-2890-IMGN151-A-next-generation-folate Rina-S har DAR 6 med topoisomerase 1 inhibitor som payload. Hvilket stof der er bedst må tiden vise. Jeg har ikke fundet data på patienter fra IMGN151.

[E_L]

DAR of 8 I believe

[gentogen]

Hej Raun. Jeg tænkte sjovt nok lidt det samme, da jeg læste meddelelsen

[Solsen]

Correct DAR8 - Rina-S is an ADC comprised of a folate receptor-alpha-directed antibody conjugated to sesutecan, ProfoundBio’s novel, proprietary hydrophilic exatecan-based linker-drug, LD038, at a homogeneous drug-to-antibody ratio (DAR) of 8. Exatecan is a highly potent, membrane permeable topoisomerase-1 inhibitor with strong bystander effect that has been extensively studied as a small molecule anticancer agent. Sesutecan is a highly hydrophilic stable, cleavable linker designed to mask the

[Solsen]

hydrophobicity of conjugated exatecan on the ADC, enabling high DAR and efficient delivery of the exatecan payload to tumors while maintaining favorable physicochemical and pharmacokinetic properties of the ADC.

[gentogen]

Ifølge det tidligere link til omtalen af Abbvies sagsanlæg, så er det sådan, at "ProfoundBio began filing patents and promoting its linker technology in 2021," Så de kunne have anfægtet patentet i flere år

[gentogen]

Den anklagede person er endda officiel medopfinder af ProfoundBios patent, så vedkommende har da ikke skjult sin relation til ProfoundBio, så igen: Abbvie har haft fere år, hvor de kunne have anfægtet patentet

[gentogen]

US20240207429A1 - Linkers, drug linkers and conjugates thereof and methods of using the same - Google Patents

The present invention provides Polar units, Linker intermediates, Linkers, Drug-Linkers and Conjugates thereof.

(patents.google.com)

[E_L]

Rova-T: the story of AbbVie’s multi-billion dollar failure -I'll have another look at this story tomorrow, but maybe this is also about AbbVie having a grudge with former Stemcentrx employees... https://www.science.org/content/blog-post/last-stemcentrx

[lahn1]

Everyone won big time on Stemcentrx except Abbvie. Is IMGN just another failure in the line af disasters by Abbvie ?

[lahn1]

Founder of Profound come from Stemcentrx got hired at Abbvie and left and then developed Rina-s which is better tha Elahere double whammy

[Raun]

[Solsen]

What a story

[lahn1]

Abbvie tabte en meget ligende sag mod Adcentrx. Dommeren afviste sagen grundet manglende beviser på en kriminel handling. https://casetext.com/case/abbvie-inc-v-adcentrx-therapeutics-inc?utm_source=chatgpt.com&__cf_chl_rt_tk=6cLBbJCdxo3.l47PVnxvbN5nCD55gIk5u605i6EDfmg-1742847322-1.0.1.1-dnnmMeqSOFS.oHThbMIG.pnL8_CO9u_dEtkfHwXHyc8

[transalp]

Go morgen..

[E_L]

Store fremskridt i behandling af knoglemarvskræft https://www.myelomatose.dk/nyheder/store-fremskridt-i-behandling-af-knoglemarvskraeft/